View Older Stories View More Recent Stories

Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 27, 2020 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Ionis provides fourth quarter and full year 2019 financial results
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 19, 2020 07:05AM Ionis Pharmaceuticals to hold 2019 financial results webcast
Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Feb 11, 2020 07:16AM Ionis Pharmaceuticals (IONS) treatment for Alexander disease granted orphan drug status from EMA
Feb 11, 2020 07:05AM Ionis treatment for Alexander disease granted orphan drug status from EMA
Jan 28, 2020 04:08PM Akcea Therapeutics (AKCA) and Ionis (IONS) report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 22, 2020 07:08AM Ionis Pharmaceuticals (IONS), Akcea Therapeutics (AKCA) Announce Positive Topline Phase 2 Results of AKCEA-APOCIII-L Rx
Jan 22, 2020 07:05AM Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020 07:04AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Report Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 9, 2020 07:05AM Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 7, 2020 07:05AM Ionis' neurological franchise marks year of achievement
Jan 7, 2020 07:05AM /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
Jan 6, 2020 07:05AM Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Jan 2, 2020 08:01AM Akcea Therapeutics (AKCA) Reports Publication of Results from Phase 2 Study of AKCEA-APO(a)-LRx
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Dec 19, 2019 07:08AM Ionis Pharmaceuticals (IONS) licenses investigational Alzheimer's therapy to Biogen (BIIB)
Dec 19, 2019 07:05AM Ionis licenses investigational Alzheimer's therapy
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 18, 2019 10:03PM Akcea Retains Rights to AKCEA-APOCIII-LRx
Dec 18, 2019 07:12AM Ionis Pharmaceuticals (IONS) appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Dec 18, 2019 07:05AM Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
Dec 16, 2019 07:09AM Akcea Therapeutics (AKCA) Announces Lynne Parshall, J.D. as Bpard Chair; Appoints Barbara Yanni to Board
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 16, 2019 07:00AM Akcea Therapeutics Announces New Appointments to its Board of Directors
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Dec 4, 2019 07:00AM Akcea Announces Appointment of New Chief Operating Officer
Dec 2, 2019 07:05AM Ionis Pharmaceuticals to hold technology webcast
Nov 25, 2019 07:19AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Commence NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 25, 2019 07:00AM Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
View More Recent Stories View Older Stories